Table 1:
Patient characteristics
| Esophageal adenocarcinoma (n=805) | Gastric cardia adenocarcinoma (n=300) | Non-cardia gastric adenocarcinoma (n=203) | p-value | |
|---|---|---|---|---|
| Age at cancer (years), median (IQR) | 65.5 (61.0, 71.9) | 66.7 (61.3, 73.2) | 66.7 (61.4, 75.3, | 0.13 |
| Male gender | 800 (99.4%) | 298 (99.3%) | 201 (99.0%) | 0.85 |
| Ethnicity | <0.001 | |||
| Hispanic or Latino | 14 (1.7%) | 8 (2.7%) | 24 (11.8%) | |
| Not Hispanic or Latino | 749 (93.0%) | 281 (93.7%) | 173 (85.2%) | |
| Unknown | 42 (5.2%) | 11 (3.7%) | 6 (3.0%) | |
| Race | <0.001 | |||
| White | 693 (86.1%) | 263 (87.7%) | 99 (48.8%) | |
| Black / African American | 27 (3.4%) | 19 (6.3%) | 80 (39.4%) | |
| American Indian / Alaska Native | 0 (0.0%) | 2 (0.7%) | 4 (2.0%) | |
| Asian | 1 (0.1%) | 2 (0.7%) | 2 (1.0%) | |
| Native Hawaiian / Pacific Islander | 7 (0.9%) | 2 (0.7%) | 4 (2.0%) | |
| Unknown | 77 (9.6%) | 12 (4.0%) | 14 (6.9%) | |
| Percent residing below poverty level in zip code where patient resided at cancer diagnosis | <0.001 | |||
| <10% | 204 (25.3%) | 85 (28.3%) | 38 (18.7%) | |
| 10–25% | 466 (57.9%) | 159 (53.0%) | 90 (44.3%) | |
| 25–50% | 104 (12.9%) | 40 (13.3%) | 59 (29.1%) | |
| >50%+ | 5 (0.6%) | 2 (0.7%) | 9 (4.4%) | |
| Unknown | 26 (3.2%) | 14 (4.7%) | 7 (3.4%) | |
| Ever smoker | 92 (11.4%) | 47 (15.7%) | 25 (12.3%) | 0.17 |
| Diabetes | 262 (32.5%) | 110 (36.7%) | 88 (43.3%) | 0.01 |
| Frailty Risk Category | 0.04 | |||
| Low (<5) | 430 (53.4%) | 134 (44.7%) | 95 (46.8%) | |
| Intermediate (5–15) | 261 (32.4%) | 107 (35.7%) | 70 (34.5%) | |
| High (>15) | 42 (5.2%) | 20 (6.7%) | 23 (11.3%) | |
| Unknown | 72 (8.9%) | 39 (13.0%) | 15 (7.4%) | |
| Hospital Frailty Risk Score, median (IQR) | 3.9 (1.6, 7.5) | 4.8 (2.1, 8.5) | 4.9 (2.7, 9.2) | 0.002 |
| BMI at cancer diagnosis | 0.15 | |||
| 18.5–25 | 191 (23.7%) | 79 (26.3%) | 52 (25.6%) | |
| <18.5 | 19 (2.4%) | 9 (3.0%) | 9 (4.4%) | |
| 25–30 | 241 (29.9%) | 83 (27.7%) | 76 (37.4%) | |
| 30–35 | 148 (18.4%) | 63 (21.0%) | 30 (14.8%) | |
| 35+ | 74 (9.2%) | 24 (8.0%) | 14 (6.9%) | |
| Unknown | 132 (16.4%) | 42 (14.0%) | 22 (10.8%) | |
| Premorbid BMI | 0.05 | |||
| 18.5–25 | 105 (13.0%) | 45 (15.0%) | 46 (22.7%) | |
| <18.5 | 4 (0.5%) | 3 (1.0%) | 1 (0.5%) | |
| 25–30 | 231 (28.7%) | 88 (29.3%) | 61 (30.0%) | |
| 30–35 | 163 (20.2%) | 52 (17.3%) | 41 (20.2%) | |
| 35+ | 101 (12.5%) | 40 (13.3%) | 20 (9.9%) | |
| Unknown | 201 (25.0%) | 72 (24.0%) | 34 (16.7%) | |
| Percent change in weight from premorbid weight to cancer diagnosis, median (IQR) | 4.9 (0.3, 9.6) | 6.0 (1.2, 10.6) | 4.5 (0.5, 8.8) | 0.27 |
| Clinical stage | 0.001 | |||
| Locally advanced | 601 (74.7%) | 198 (66.0%) | 131 (64.5%) | |
| Regional | 204 (25.3%) | 102 (34.0%) | 72 (35.5%) | |
| Follow up time, median (IQR) | 1.9 (0.9, 4.6) | 2.0 (1.0, 4.7) | 2.7 (1.3, 6.0) | 0.01 |
| Deceased | 666 (82.7%) | 246 (82.0%) | 146 (71.9%) | 0.002 |